WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573991
Description: N6-Cyclohexyladenosine is an adenosine receptor agonist. It selectively binds to adenosine A1 receptors over A2 receptors. N6-Cyclohexyladenosine decreases heart rate, increases coronary flow, and induces sleep. N6-Cyclohexyladenosine also decreases locomotor activity in mice.
MedKoo Cat#: 573991
Chemical Formula: C16H23N5O4
Exact Mass: 349.175
Molecular Weight: 349.39
Elemental Analysis: C, 55.00; H, 6.64; N, 20.04; O, 18.32
IUPAC/Chemical Name: N-cyclohexyl-adenosine
InChi Key: SZBULDQSDUXAPJ-XNIJJKJLSA-N
InChi Code: InChI=1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
SMILES Code: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H]1O)N2C=NC3=C(NC4CCCCC4)N=CN=C32
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 349.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Hutchison, A.J., Webb, R.L., Oei, H.H., et al. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251(1), 47-55 (1989).
2. Blanco-Centurion, C., Xu, M., Murillo-Rodriguez, E., et al. Adenosine and sleep homeostasis in the basal forebrain. J Neurosci. 26(31), 8092-8100 (2006).
3. Nikodijević, O., Daly, J.W., and Jacobson, K.A. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 261(1), 67-70 (1990).